European cancer mortality predictions for the year 2026: the levelling of female lung cancer mortality.
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND] We provided updated cancer mortality estimates for 2026 in the European Union (EU) and its five most populous countries, with a focus on lung cancer.
APA
Santucci C, Mignozzi S, et al. (2026). European cancer mortality predictions for the year 2026: the levelling of female lung cancer mortality.. Annals of oncology : official journal of the European Society for Medical Oncology, 37(4), 555-564. https://doi.org/10.1016/j.annonc.2025.12.005
MLA
Santucci C, et al.. "European cancer mortality predictions for the year 2026: the levelling of female lung cancer mortality.." Annals of oncology : official journal of the European Society for Medical Oncology, vol. 37, no. 4, 2026, pp. 555-564.
PMID
41554652 ↗
Abstract 한글 요약
[BACKGROUND] We provided updated cancer mortality estimates for 2026 in the European Union (EU) and its five most populous countries, with a focus on lung cancer.
[MATERIALS AND METHODS] Cancer death certifications and population data were obtained from the World Health Organization and United Nations databases. For the EU, France, Germany, Italy, Poland, Spain, and the UK, we derived data for all cancers combined and major cancer sites since 1970. Linear regression models, based on the most recent age-specific trends identified by Poisson joinpoint regression, were used to estimate deaths in 2026. The number of averted deaths between 1989 and 2026 was computed by applying the 1988 peak rate to subsequent populations.
[RESULTS] For 2026, we estimated ∼1 230 000 EU cancer deaths, corresponding to age-standardised rates of 114.1/100 000 males (-7.8% versus 2020-2022) and 74.7/100 000 females (-5.9%). In the EU countries and the whole EU, favourable trends are predicted for most major cancers, except female pancreatic cancer. In the UK, predicted rates are also favourable, except female colorectal cancer. Lung cancer mortality continues to decrease markedly among males, while we predicted a levelling off of rates, around 12.5/100 000, among females in all considered countries and the whole of EU, except for Spain (+2.4%). Among females, lung cancer mortality declines are confined to those aged <65 years, while unfavourable trends continued in older age groups. Around 7.3 (5.0 in males, 2.3 in females) million total cancer deaths have been avoided in the EU since the peak observed in 1988. The corresponding figure for lung cancer is 1.8 million among males, while no averted deaths were recorded among females.
[CONCLUSION] Lung cancer mortality predictions for 2026 indicate a levelling off among EU females, with age- and country-specific differences. Mortality trends in ASRs for most cancers remain favourable in the EU and the UK, though the absolute number of cancer deaths is not declining due to population ageing.
[MATERIALS AND METHODS] Cancer death certifications and population data were obtained from the World Health Organization and United Nations databases. For the EU, France, Germany, Italy, Poland, Spain, and the UK, we derived data for all cancers combined and major cancer sites since 1970. Linear regression models, based on the most recent age-specific trends identified by Poisson joinpoint regression, were used to estimate deaths in 2026. The number of averted deaths between 1989 and 2026 was computed by applying the 1988 peak rate to subsequent populations.
[RESULTS] For 2026, we estimated ∼1 230 000 EU cancer deaths, corresponding to age-standardised rates of 114.1/100 000 males (-7.8% versus 2020-2022) and 74.7/100 000 females (-5.9%). In the EU countries and the whole EU, favourable trends are predicted for most major cancers, except female pancreatic cancer. In the UK, predicted rates are also favourable, except female colorectal cancer. Lung cancer mortality continues to decrease markedly among males, while we predicted a levelling off of rates, around 12.5/100 000, among females in all considered countries and the whole of EU, except for Spain (+2.4%). Among females, lung cancer mortality declines are confined to those aged <65 years, while unfavourable trends continued in older age groups. Around 7.3 (5.0 in males, 2.3 in females) million total cancer deaths have been avoided in the EU since the peak observed in 1988. The corresponding figure for lung cancer is 1.8 million among males, while no averted deaths were recorded among females.
[CONCLUSION] Lung cancer mortality predictions for 2026 indicate a levelling off among EU females, with age- and country-specific differences. Mortality trends in ASRs for most cancers remain favourable in the EU and the UK, though the absolute number of cancer deaths is not declining due to population ageing.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Cancer mortality in Europe in 2020, and an overview of trends since 1990.
- Cancer mortality predictions for 2026 in selected Asian countries and Australia with focus on prostate cancer.
- European cancer mortality predictions for the year 2025 with focus on breast cancer.
- Dietary vitamin D and gastric cancer risk within the stomach cancer pooling (stop) project.
- Cancer mortality predictions for 2024 in selected Asian countries and Australia with focus on stomach cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.